Faster onset of action of rapid acting insulin analogues has improved postprandial glycaemic control in patients with type 2 diabetes [37,38,47,52–54]; and more predictable glycaemic lowering profiles of the insulin analogues have also led to reductions in reported nocturnal hypoglycaemia, particularly comparing long-acting insulin analogues with NPH. This evidence concerns the gene INS and type 2 diabetes mellitus.